HIGHLIGHTS

HIGHLIGHT ADVISORS

DAVID BLAUSTEIN

THE GALLEON GROUP, NEW YORK, NY, USA

ERIK DE CLERCQ

KATHOLIEKE UNIVERSITEIT LEUVEN, BELGIUM

RODERICK FLOWER

WILLIAM HARVEY RESEARCH INSTITUTE, QMW, LONDON, UK

F. PETER GUENGERICH VANDERBILT UNIVERSITY NASHVILLE, TN, USA

FRANZ HEFTI

MERCK RESEARCH LABORATORIES, SAN DIEGO, CA, USA

JOAN HELLER BROWN

UNIVERSITY OF CALIFORNIA SAN DIEGO, CA, USA

MADS KROGSGAARD THOMSEN

NOVO NORDISK, BAGSVAERD, DENMARK

HUGO KUBINYI UNIVERSITY OF HEIDELBERG,

GERMANY JULIO LICINIO

UNIVERSITY OF CALIFORNIA LOS ANGELES, CA, USA

CHRISTOPHER LIPINSKI

PFIZER GLOBAL RESEARCH AND DEVELOPMENT, GROTON, CT, USA

LESLIE MEYER-LEON IP LEGAL STRATEGIES GROUP, OSTERVILLE, MA, USA

TOMI SAWYER ARIAD PHARMACEUTICALS.

CAMBRIDGE, MA, USA

GEORGE SCHLICH MATHYS & SQUIRE,

LONDON, UK

JANET WOODCOCK CENTER FOR DRUG EVALUATION AND RESEARCH, WASHINGTON, MD, USA

OBESITY

PPARγ2 piles on the pounds

Weakness for snacks. Unused gym membership. Taking the lift, not the stairs. All could be blamed for a few extra inches on our waistlines. Now, as two papers in *Genes & Development* reveal, a key culprit — albeit at the molecular level — is the γ 2 isoform of the peroxisome proliferator-activated receptor (PPARy2).

PPARy, a nuclear hormone receptor that regulates gene expression, has received much attention in recent years, in part owing to its emerging link with fat-cell development, or adipogenesis. PPARy and another transcription factor, C/EBPa, are both known to be crucial in adipogenesis, but their exact role has been hard to establish, as they positively regulate each other's expression. Although previous studies have shown that addition of PPARy can induce adipogenesis in the absence of C/EBPa, it was not known whether the converse was true. As described in the first of the two papers, researchers in Bruce Spiegelman's lab have clarified this issue by generating a cell line lacking PPARy. They used this cell line to show that C/EBPa has no ability to promote adipogenesis in the absence of PPARy, thus indicating that PPARy is the key regulator in a single adipogenic pathway, rather than PPARy and C/EBPa each being able to act independently to promote adipogenesis.

However, PPAR γ has two main isoforms, PPAR γ 1 and PPAR γ 2. Although their expression patterns differ — PPAR γ 1 is expressed in

whereas PPARy2 expression is fat-cell specific — the two isoforms are expressed at comparable levels in fat cells, so their relative importance to adipogenesis was not clear. This question was addressed by Heidi Camp and colleagues in the second paper. Using transcriptional repressors engineered to bind specifically to the PPARy gene via novel zinc fingers, they created cells lacking PPARy, which, as in previous work, were unable to develop into fat cells. Then, by selectively restoring the expression of either PPARy1 or PPARy2 using retroviruses, they showed that only PPARy2 could reactivate adipogenesis.

various cells including fat cells,

These advances in our understanding of adipogenesis further the hope that rational manipulation of this process could be a therapeutic strategy for combating obesity. However, in animal models, direct and powerful inhibition of adipogenesis leads to lipodystrophy, indicating that a more measured approach — for example, pharmacological reduction of PPARy in a controlled manner — is likely to be a necessity.

Peter Kirkpatrick

References and links ORIGINAL RESEARCH PAPERS Rosen, E. D. et al.

C/EBPα induces adipogenesis through PPAR_Y: a unified pathway. *Genes Dev.* **16**, 22–26 (2002) | Ren, D. *et al.* PPAR_Y knockdown by engineered transcription factors: exogenous PPAR_Y2 but not PPAR_Y1 reactivates adipogenesis.*Genes Dev.* **16**, 27–32 (2002)

FURTHER READING Rosen, E. D. *et al.* PPAR_Y is required for the differentiation of adipose tissue *in vivo* and *in vitro*. *Mol. Cell* **4**, 611–617 (1999)